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Abstract
Tourette syndrome (TS) is a childhood-onset neuropsychiatric disorder characterized by the presence of multiple
motor and vocal tics. TS usually co-occurs with one or multiple psychiatric disorders. Although behavioral and
pharmacological treatments for TS are available, some patients do not respond to the available treatments. For
these patients, TS is a severe, chronic, and disabling disorder. In recent years, deep brain stimulation (DBS) of basal
ganglia-thalamocortical networks has emerged as a promising intervention for refractory TS with or without
psychiatric comorbidities. Three major challenges need to be addressed to move the field of DBS treatment for
TS forward: (1) patient and DBS target selection, (2) ethical concerns with treating pediatric patients, and (3) DBS
treatment optimization and improvement of individual patient outcomes (motor and phonic tics, as well as
functioning and quality of life). The Tourette Association of America and the American Academy of Neurology have
recently released their recommendations regarding surgical treatment for refractory TS. Here, we describe the
challenges, advancements, and promises of the use of DBS in the treatment of TS. We summarize the results of
clinical studies and discuss the ethical issues involved in treating pediatric patients. Our aim is to provide a better
understanding of the feasibility, safety, selection process, and clinical effectiveness of DBS treatment for select cases
of severe and medically intractable TS.
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Background
Tourette syndrome (TS) is a relatively common neuro-
psychiatric disorder characterized by sudden, rapid, re-
petitive, non-rhythmic, and stereotyped movements and/
or vocalizations. Diagnosis of TS requires the presence
of both multiple motor tics and at least one phonic tic,
with a childhood-onset and a duration of more than one
year [1]. The prevalence of TS is 0.3–0.8% in children [2,
3]. Tics usually emerge around age 7, and may wax and
wane in frequency [4]. TS is frequently complicated by
the presence of one or more comorbid psychiatric disor-
ders, particularly attention deficit hyperactivity disorder
(ADHD), obsessive-compulsive disorder (OCD), impulse
control disorder (ICD), and/or a mood disorder [5–7].
Severity of symptoms vary among patients and for many,
tics gradually become less severe during adolescence and
most of them disappear in early adulthood [8]. Current
treatments for TS mainly involve behavioral interven-
tions and pharmacotherapy, especially α2 adrenergic
agonists, dopamine antagonists, dopamine depleters,
benzodiazepines, antiepileptic drugs, and botulinum
toxin injections [9–12]. However, for some patients’ TS
is a severe and chronic disorder that does not respond
to conventional pharmacological or behavioral treat-
ments. Moreover, some of these patients develop what
has been coined by some experts as “malignant TS”
which can result in hospitalizations and/or self-injurious
behaviors (e.g., cervical myelopathy, bone fractures, ret-
inal detachment). Some patients with malignant TS may
experience temporary or permanent disabilities [13–16].
Neurosurgical intervention, such as deep brain stimula-
tion can be used to optimize care of selected individuals
with malignant TS [17].
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Recently, both DBS and ablative neurosurgical proce-
dures have been utilized in an effort to manage refrac-
tory symptoms in TS patients [18–21]. In contrast to
DBS, ablative surgery is not reversible and uncertainty
exists whether ablative techniques work better in terms
of clinical effectiveness and adverse event-profile. For ex-
ample, bilateral thalamic lesions have been associated
with impaired speech, swallowing difficulties, and cogni-
tive deficits [22]. Moreover, substantial clinical evidence
exists for the effectiveness of DBS in hyperkinetic move-
ment disorders, such as tremor, tardive dyskinesia, and
chorea [23–25]. It is believed that the pathophysiology
of TS is closely linked to the dysfunction of cortico-
striato-pallido-thalamo-cortical networksand that the
modulation of these networks could alleviate the clinical
symptoms of TS [26, 27]. Large inter-individual differ-
ences have been observed in the clinical symptoms of
TS, along with the type and severity of psychiatric co-
morbidities, and clinical response to DBS. In order to
move the field of DBS treatment for TS forward and to
improve individual patient outcomes, at least three
major challenges need to be addressed: [1] patient and
target selection, [2] ethical issues involved in treating
pediatric patients, and [3] optimization of DBS, such as
motor and vocal tics, mental health, daily functioning,
and quality of life. In this article, we outline the chal-
lenges, progress, and promises of DBS treatment for TS.
We evaluate the results of clinical studies and discuss
several methodological and ethical issues involved in
DBS treatment of pediatric patients. The aim of this re-
view is to provide a better understanding of the feasibil-
ity, safety, and effectiveness of DBS treatment for
carefully selected cases of severe and intractable TS.
Main text
Surgical treatment
In this review, we consider TS in terms of the diagnostic
criteria of the DSM-V. The main classifier is the pres-
ence of tics, which can be categorized as motor and
phonic tics, and further divided into simple and complex
tics. Simple motor tics can affect any body part, but they
commonly appear in the face, such as eye blinking, rais-
ing the eyebrows, head jerking, or tongue protrusion.
Some patients also manifest complex motor tics, such as
grimacing, echopraxia (imitating others’ movements),
copropraxia (e.g., performing socially inappropriate ges-
tures or inappropriate touching) or, in rare cases, self-
injurious behavior (e.g., self-hitting, self-biting, pounding
on objects). Additionally, the diagnostic criteria for TS
requires that the patient presents with or has a history
of phonic tic(s). Common simple phonic tics include
sniffing, throat clearing, coughing, yawning, or making
other simple meaningless sounds. Complex phonic tics
include echolalia (repeating others’ words or phrases),
coprolalia (yelling out socially inappropriate words or
phrases) or verbigeration (repeating a word rapidly and
involuntarily) [28].
Most individuals diagnosed with TS present with one
or more comorbid psychiatric disorders. In one cross-
sectional study of 1374 TS participants, approximately
86% met diagnostic criteria for one or more psychiatric
comorbidities [29]. The psychiatric disorders that most
commonly co-occur with TS are ADHD, OCD, sleep
disorders, anxiety disorders, and depressive disorders
[30]. Psychiatric comorbidities remain an issue of con-
cern in DBS treatment for TS because the symptoms
can be severe, chronic, and may have a greater impact
on the patient’s functioning and quality of life compared
to motor and phonic tics. The Revised 2006 Guideline of
the Tourette Association of America (TAA) Database/
Registry Group recommends the following prior to initi-
ating DBS, 1) the patient’s psychiatric comorbidities be
stabilized and 2) no active suicide or homicidal ideation
for six months [17].
Clinician-researchers have collectively gravitated to a
disease-centered approach to DBS for TS. This includes
meticulous attention to patient selection [17], collection
and analysis of standardized data [31], and engagement
of multiple centers to identify patterns of symptoms and
to improve outcomes [4]. Additionally, much effort has
been put into identifying appropriate targets for DBS.
Data from the TAA’s DBS Registry and Database have
indicated that many different regions/structures located
within the cortico-striato-pallido-thalamo-cortical net-
work are promising targets [32].. In the next sections, we
discuss some of the most promising DBS targets for TS
treatment. Table 1 and Fig. 1 provide an overview of
recent DBS treatment studies of patients with severe and
refractory TS. The list is meant not to be exhaustive but
rather to illustrate some of the current approaches in
the field.
Single target
Thalamus
To date, the majority of TS DBS treatment studies has
focused on the thalamus due to its strategic location
between motor areas of the cerebral cortex and motor-
related subcortical structures, particularly the basal
ganglia and cerebellum [33, 34]. A retrospective study of
several patients with refractory TS and psychiatric
comorbidities reported that DBS of the thalamic
centromedian-parafascicular (CM-Pf) complex was asso-
ciated with a 46% improvement in motor tics and 52%
improvement in phonic tics, as measured by the Yale
Global Tic Severity Scale (YGTSS) at follow-up (mean
duration: 26 months) [34]. Moreover, DBS of this thal-
amic region markedly improved the patients’ social, oc-
cupational, and educational functioning. Furthermore,
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two case studies reported that DBS of the thalamic CM-
Pf improved comorbid OCD, anxiety, and depression, as
assessed by the Yale-Brown Obsessive Compulsive Scale
(Y-BOCS), Beck Anxiety Inventory (BAI), Symptoms
Checklist List 90 (SCL90), and Beck Depression Inven-
tory (BDI) [35, 36]. Several other case reports and case
series have reported that DBS of the CM-Pf region can
alleviate motor tic severity as well as comorbid psychi-
atric symptoms in patients with TS [37, 38].
In addition, one study reported that DBS of the medial
thalamic region produced a mean 50% improvement in
overall tic severity (YGTSS total score) at 6-month
follow-up [37]. Interestingly, the active lead location was
in the region of the posterior ventralis oralis internus/
CM-Pf complex [37], suggesting that the CM-Pf com-
plex may have partially mediated the beneficial effects of
the medial thalamus DBS on TS symptoms. This effect
on TS symptom severity could stem from the modula-
tion of excitatory fibers of the CM-Pf projecting to the
striatum and subthalamic nucleus, although this hypoth-
esis remains speculative [60]. In contrast to its effect on
tic severity, DBS of the medial thalamus did not produce
an overall, group mean improvement in the patients’ Y-
BOCS scores [37]. However at the individual level, about
63% of the patients with TS achieved a greater than 50%
reduction in their Y-BOCS scores and one patient expe-
rienced an increase in OCD symptoms [37]..
In a prospective open-label trial, DBS of the ventral
anterior and ventrolateral motor parts of the thalamus
was similarly effective in reducing tic severity in 8
patients with TS and psychiatric comorbidities [38].
Additionally, DBS improved the patients’ anxiety, adap-
tive functioning, and quality of life,owever, no significant
effects were observed on comorbid symptoms of OCD
(Y-BOCS), anxiety (State-Trait Anxiety Inventory,
STAI), and depression (BDI) [38]. Thus, these studies
suggest that DBS of each thalamic region can reduce tic
severity and to some extent, improve comorbid anxiety
and depression [61]. Only DBS of the CM-Pf has been
reported to alleviate comorbid OCD symptoms in some
cases of TS.
In general, DBS of the thalamus has been well toler-
ated, but patient risk and adverse side effects remain an
issue of concern. Reported side effects include the tran-
sient blurring of vision, dysarthria, recurrent tension
headache, and a single seizure-like episode (after DBS of
the CM-Pf [34, 36]). Disturbances of eye motility have
also been documented, as well as impaired fine motor
skills, particularly following DBS of the ventral anterior
and ventrolateral motor thalamic regions [38]. Motor
side-effects of thalamic stimulation is likely larger given
that it occurs as the simulation increases. Emotional dis-
turbances, erectile dysfunction, paresthesia, weight gain,
and apathy may also be observed in some patients after
Fig. 1 Quantitative susceptibility map of targets proposed for DBS in Tourette’s syndromeAbbreviations: ALIC, anterior limb of internal capsule;
amGPi, anteromedial or limbic GPi; CM-Pf, centromedian-parafascicular complex; GPe, Globus Pallidus externus; NAc, Nucleus Accumbens; pvGPi,
posteroventral GPi.
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thalamic DBS [27]. Of note, the development of the
latter side effect is somewhat surprising as apathy has
traditionally been linked to lesions of basal ganglia struc-
tures altering the cortico-striatal-pallidal-thalamic-cor-
tical pathways [62]. In some patients, the side effects
associated with thalamic DBS can outweigh its thera-
peutic benefit over the long-term course of treatment,
necessitating the exploration and modulation of a target
other than the thalamus for the patients with TS [39].
Globus Pallidus
The globus pallidus (GP) is a promising DBS target for
managing severe and refractory TS [63]. As alluded to
earlier, the GP is an element of the basal ganglia-
thalamocortical circuit that is believed to play a crucial
role in the control of motor function. The GP, consisting
of the internal segment (GPi) and the external segment
(GPe), participates in both the direct and indirect motor
pathways. Some experts have hypothesized that the GP
modulates the excitability of the thalamus and influences
the input from thalamus to cortex [64]. A recent resting-
state functional magnetic resonance imaging (fMRI)
study indicates that the GP could be involved in TS
pathophysiology [63],owever, the putative role of the GP
in TS remains to be clearly defined.
A randomized, double-blind, crossover clinical trial
assessed the utility of bilateral GPi DBS in alleviating TS
motor symptoms [40]. In this study, 14 patients were
randomly allocated to receive either stimulation on-first
or stimulation off-first for 3 months, followed by a
switch to the opposite condition for an additional 3-
month period. Thirteen patients completed assessments
during both blinded treatment conditions. The results
revealed that tic severity of these patients, as determined
by the mean YGTSS total score, was reduced by an
approximate 15% (95% CI: 5–25%) during the on-
stimulation period compared to the off-stimulation
period. Moreover, bilateral anterior GPi DBS reduced
the severity of comorbid depression (BDI) compared to
baseline prior to surgery. The stimulation had no signifi-
cant effects on comorbid OCD symptoms (Y-BOCS) and
anxiety (BAI) during an open-label period [40].
DBS of the limbic or anteromedial GPi (amGPi) has
been successfully applied to TS treatment. In one study,
15 patients with severe and refractory TS were treated
with amGPi DBS and clinically assessed before surgery
and between 17 and 82 months after surgery [32]. The
results showed that the patients’ tic severity was signifi-
cantly reduced at follow-up (mean reduction of YGTSS
total score: 38%; phonic score: 38%; motor score: 33%)
[32]. At the group level, amGPi DBS had no significant
effect on comorbid OCD (Y-BOCS), depression (BDI),
and anxiety (BAI). However, the authors identified a
subgroup of patients with severe baseline OCD
symptoms as defined by Y-BOCS who had a 39%
improvement after amGPi DBS [32].. Although this
study found no overall effect on depression, other stud-
ies have reported an improvement in comorbid depres-
sion following amGPi [41, 42, 65]. In another study, DBS
was targeted on the anterior GPi, which produced a
significant tic improvement but failed to alleviate the
patients’ comorbid anxiety and depression [43].
A multicenter study of TS patients with medial GPi
DBS reported improvements in tic severity, comorbid
OCD, anxiety, depression andquality of life [42]. The
median time to achieve a clinical response (≥ 40% reduc-
tion in YGTSS total score) was 13 months. In this study,
the clinical outcomes of TS patients treated with GPi
were compared with the outcomes of patient who had
been treated with DBS of other targets, including the
CM thalamus. No significant differences in the strength
or timing of the clinical response were observed across
the different DBS targets, although the response to GPi
stimulation wasslower than thalamic CM stimulation
(18 months, 95% CI: 12–24 vs 11 months, 95% CI: 6–15).
Finally, a retrospective study reported that posteroven-
tral GPi DBS improved motor tics in 3 teenagers with
refractory TS [44]. Posteroventral GPi DBS also stabi-
lized comorbid OCD symptoms present in one patient.
These findings suggest that posteroventral GPi DBS
could serve as a safe and effective intervention for man-
aging both tic and OCD symptoms in select adolescent
patients who suffer from TS.
GPi DBS has been associated with various adverse
events and side effects. For example, 3 patients (out of a
total of 13 patients) experienced significant adverse
events (2 patients developed DBS hardware-related
infections and 1 patient a DBS-induced hypomania) fol-
lowing amGPi DBS [40]. All adverse side effects were
managed or resolved over the treatment course. Also,
amGPi DBS has been associated with weight gain, dizzi-
ness, feelings of nausea, freezing-of-gait episodes, im-
paired speech articulation, and akathisia [32]. Similarly,
posteroventral GPi DBS has been associated with
dysarthria [44], dystonia, and dyskinesias [4].
The prior studies reviewed have focused on the GPi
but have not explored the GPe as a potentially effective
DBS target for TS treatment. A recent study examined
tonic and phasic neuronal activities in the anterior GPe
and GPi in 8 awake patients with TS while DBS elec-
trodes were implanted [66]. The results showed that the
expression of tics was accompanied by tonic and phasic
changes of neuronal activity throughout the GP. A large
fraction of both GPe and GPi neurons changed their
baseline firing rate around the time of the tics, indicating
that both GP segments could have a role to play in TS
pathophysiology. Indeed, a case report described a 47-
year-old patient with refractory TS who showed marked
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improvements in tics and mental health status following
bilateral GPe DBS [45]. Moreover, when the stimulation
was unexpectedly interrupted due to battery depletion,
some of the patient’s TS symptoms reemerged. These
findings suggest that the GPe can also be considered as
a potentially effective DBS target for managing severe
and refractory TS.
Nucleus accumbens and anterior limb of the internal
capsule
A few case studies have assessed the utility of DBS of
the nucleus accumbens (NAc) and the anterior limb of
the internal capsule (ALIC) in TS treatment. One report
of a 26-year-old patient with TS had a 50% reduction in
tic severity after bilateral NAc DBS [46]. Other case re-
ports confirmed the beneficial effects of DBS of the
NAc, as well as of the ALIC, on the severity of tics [47,
48]. In one of these case studies, the patient had a 57%
reduction in tic severity (assessed by the YGTSS) and a
90% reduction in OCD symptom severity (Y-BOCS) at
1-month follow-up [47]. Similarly, another case report of
a 38-year-old TS patient reported a 53% reduction in
OCD symptoms at 3-month follow-up, which was sus-
tained until 36-month follow-up [48]. In the latter study,
however, the patient continued experiencing recurrent
depressive episodes [49]. This observation highlights a
caveat to the treatment, namely that DBS of the NAc/
ALIC region may induce affective side effects, including
both depression and hypomania [46].
In conclusion, all the brain targets reviewed so far have
shown some effectiveness in managing severe and refrac-
tory TS. A recent meta-analysis (57 studies, including a
total of 156 patients) showed that DBS treatment was as-
sociated with an overall 53% improvement in tic severity
scores on the YGTSS, with no significant differences be-
tween the targets examined (thalamus, posteroventrolat-
eral part and the anteromedial part of the GPi, NAc, and
ALIC) [27]. Data from the TAA Registry are in line with
these results [4].
Other targets
Some studies reported clinical improvements in patients
with TS when the DBS was targeted on the junction of
multiple adjacent thalamic nuclei [27, 38]. An alternative
target involves the Forel’s field H1, through which the
projections from GPi to thalamus pass. This area was
found to be an effective and well-tolerated alternative
target in two cases of refractory TS [51]. According to
the authors, stimulation of the H1 field could normalize
a decreased output of the GP through retrograde stimu-
lation of the GPi. The authors further speculate that
DBS of Forel’s field H1 could help to restore the balance
between the direct, indirect, and hyper-direct motor
pathways, ultimately limiting excessive activity of the
thalamo-cortical network in TS. Moreover, DBS of
Forel’s H1 field has been found to relieve comorbid de-
pression and anxiety in two cases of refractory TS [51].
In one of the two cases, the stimulation of this
target also improved the patient’s comorbid OCD symp-
toms. Targeting Forel’s H1 field has the advantage over
direct thalamic stimulation because DBS of the H1 field
can be performed at low stimulation intensities, reducing
both stimulation-related adverse events and battery de-
pletion. However, the precise anatomical localization of
this region is difficult to identify using current imaging
or other neurophysiologal techniques, limiting its poten-
tial clinical use at the present time.
Finally, the subthalamic nucleus (STN) is the most
common target for DBS treatment for Parkinson disease
(PD), but some evidence exists that this target may also
be effective for managing TS symptoms. For example, it
has been reported that a 38-year-old patient with PD
who also suffered from TS showed a 89% improvement
in tic frequency after 6 months and a 97% improvement
after 12 months of bilateral STN-DBS treatment [52].
This report indicates that STN DBS may modulate dys-
function of both limbic and sensorimotor areas and that
this stimulation may provide a quicker relief of tics than
seen following medial thalamus or GPi stimulation. In
another study, 4 patients with TS received DBS of both
the bilateral GPi and bilateral STN. The researchers also
obtained recordings of local field potentials and the elec-
tromyogram from the patients between 3 and 5 days
after DBS implantation [56]. The results were taken to
indicate that STN and GPi stimulation can improve
acute TS symptoms by modulating neuronal oscillations
in the basal ganglia. However, the GPi DBS showed a
better clinical effect on OCD than STN DBS. Nonethe-
less, the available database is extremely small and further
studies are required to assess whether or not the STN is
an effective DBS target for TS treatment.
Multiple targets
It has become increasingly clear that DBS of a single
target is insufficient to manage the clinical symptoms of
all patients, given the heterogeneity and complexity of
the TS syndrome itself and the presence of large inter-
individual differences in clinical response to DBS treat-
ment. For certain symptoms, the use of multiple targets
could have a more effective or widespread effect com-
pared to the use of a single target. For example, DBS of
multiple targets could aid in managing severe psychiatric
comorbidities in some select patients with TS. A recent
case report illustrates the feasibility and effectiveness of
such a strategy [54]. In this study, DBS targeting simul-
taneously the CM-Pf complex and ventral capsule/ven-
tral striatum (VC/VS) was found to produce widespread
clinical benefits in a 20s male patient with TS and
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comorbid major depressive disorder, OCD, and opioid
use disorder. The patient’s YGTSS, YBOCS, and
Hamilton Depression Scale (HAMD) scores were im-
proved by 84, 70, and 95%, respectively, after one year of
bilateral, dual-target DBS. Also, the patient’s dependence
for opiate medications was improved and he had self-
tapered off the medication [54].
Multiple DBS targets also play a role in “rescue” DBS
treatment, where the patient receives a second lead
placement in a different target following a suboptimal
clinical response to the initial surgery [53]. Although the
use of multiple targets may have clinical value, this strat-
egy carries an increased surgical risk, risk of adverse side
effects, and complications relative to the use of a single
target. Therefore, a clear understanding of the benefits
and risks associated with the use of multiple targets,
along with adequate patient selection is required when
adopting this therapeutic strategy.
DBS combined with radiosurgery to address psychiatric
comorbidity
To date, only a few studies have explored the use of
DBS combined with stereotactic radiosurgery for man-
aging refractory TS and psychiatric comorbidities. A re-
cent case study [55] illustrates the potential utility of this
treatment strategy. In this study, a 47-year-old female
patient with refractory TS and comorbid OCD had a
poor clinical response (YGTSS = 39/50, Y-BOCS = 28/
40) to her first surgical treatment involving posteroven-
trolateral GPi DBS. One year after the first surgery, a
second DBS device was implanted in the contralateral
ventral anterior and ventrolateral motor regions of the
thalamus, which produced a significant improvement in
motor and vocal tics (YGTSS = 10/50) but did not
change the severity of her OCD symptoms (Y-BOCS =
28/40). Two years after the second DBS surgery, the
patient received gamma knife surgery targeting the
ventral portions of the ALIC. Following this interven-
tion, the severity of her comorbid OCD symptoms
was greatly reduced at 9-month follow-up. The pa-
tient was in clinical remission at 12-month follow-up
(Y-BOCS = 6/40). The remission of her OCD was ac-
companied by improvements in depressive symptoms
[55]. This case report implies that DBS combined
with radiosurgery could alleviate severe psychiatric
comorbidities in select cases of TS.
This notion seems to be supported by a retrospective
study of 10 patients with refractory TS and psychiatric
comorbidities [57]. In this study, patients had been
treated with GPi DBS combined with bilateral anterior
capsulotomy. The results showed significant improve-
ments in patients’ motor and verbal tics (YGTSS), as
well as in the severity of their comorbid psychiatric
disorders, mainly consisting of OCD and affective
disorders. Moreover, the patients’ social functioning and
quality of life were substantially improved after the com-
bined neurosurgical treatment [57]. In addition to these
results, GPi DBS combined with capsulotomy may also
offer an effective, rapid, and tolerable intervention for
rare cases of “malignant” TS [67].
Surgical candidates
Appropriate patient selection for DBS surgery requires a
careful multidisciplinary approach. Both treatment re-
fractoriness and symptom severity are important eligibil-
ity criteria for DBS. For example, some patients with
treatment-resistant profound tics, self-injurious behavior
or even life-threatening symptom [13, 44, 68] TS is a se-
verely disabling clinical condition that warrants consid-
eration of neurosurgical intervention. According to the
recommendations of the TAA published in 2006 [17],
only patients who are older than 25 years should be eli-
gible for DBS trials, although the risk of surgical compli-
cations and adverse events does not appear to be greater
among reported cases of TS under 25 years of age who
had documented DBS [17]. The TAA’s updated recom-
mendation in 2015 [58], no longer specifies an age limit
for DBS trials. A multidisciplinary team that careful con-
siders the medical and ethical issues involved in DBS
treatment should guide patient selection while ensuring
patient rights, safety, and care.
The American Academy of Neurology (AAN) has
recently published recommendations for the optimal
management of TS [58, 68]. This includes the use of a
multidisciplinary screening team pre- and post-
operatively, offering cognitive behavioral therapy to pa-
tients, screening for psychogenic/functional tics, and
mental health assessments conducted by a psychiatrist
pre- and post-operatively to confirm the DSM-V diagno-
sis and assess psychiatric comorbidities.
Effects of DBS in childhood
A retrospective case series reported the clinical out-
comes of 13 patients treated with medial thalamic DBS
for refractory TS [37]. The average age was 20 years (12
patients were younger than 25 years and 1 patient was
33 years old). After DBS, the patients continued to have
tics but the overall severity of tics (YGTSS total score)
was reduced by 50% at the last (6–58 months) follow-up.
Adverse side effects and complications reported included
skin erosion, skin infection at the connector site, head-
ache, and changes in mental state secondary to obstruct-
ive hydrocephalus. A prospective case series examined
the outcomes of 3 patients with TS (19–21 years old)
treated with DBS of the bilateral CM-Pf-ventral oral
nuclei [35]. One year after DBS, the patients showed
significant reductions in tic severity and social impair-
ment. The patients’ levels of intelligence did not change
Xu et al. Translational Neurodegeneration             (2020) 9:4 Page 12 of 19
after treatment. Another study evaluated the long-term
clinical outcomes of 3 adolescents, including the then
youngest patient worldwide (12 years old at the time of
surgery), who underwent posteroventral GPi DBS for
managing refractory TS [44]. After DBS, the pediatric
patients exhibited a substantial improvement in motor
tics, although their phonic tics and psychiatric comor-
bidities were not affected. In another study, the tics of 2
patients (both 19 years old) were improved, at least to
some extent, after anterior GPi DBS [69].
Recently, a meta-analytis review of individual patient
data from DBS studies with children and adolescents
with refractory TS (N = 58; aged 12–21 years) has been
published [70]. The studies reviewed targeted the
thalamus or GPi regions. The results showed that across
patients, studies, and targets, DBS treatment was associ-
ated with a reduction in tic severity (YGTSS) by about
58% (SD = 25; p < 0.001). Moreover, DBS treatment was
associated with a reduction in comorbid OCD symptoms
(YBOCS) by 31% (SD = 45; p < 0.001) and anxiety (STAI)
by 40% (SD = 20; p < 0.001) [70]. Although both targets
were associated with significant tic improvements,
greater improvements in tic severity were observed in
thalamic stimulation compared to pallidal stimulation
(YGTSS score improvement: thalamus: 69%; GPi: 53%;
p = 0.0387), especially in patients with less severe TS
symptoms at baseline. Additionally, the presence of co-
morbid depression was associated with a less favorable
response to DBS treatment. Side effects were noted in
about 28% of the patients however most were considered
mild. The main results from this meta-analysis are con-
gruent with the data from the TAA Registry (including
data from pediatric patients aged 13 years and older) [4].
In summary, DBS is a treatment option for adolescent
patients who suffer from severe and intractable TS and
have undergone careful assessment and selection by a
multidisciplinary team [17, 58, 69, 70]. Early DBS inter-
vention in younger patients is still controversial, given
the possibility of resolution of symptoms later in life
without DBS. Some experts argue that even though the
possibility of symptom resolution at a later age exists, an
earlier DBS intervention in select pediatric patients may
improve their social adjustment and clinical outcomes
[71]. More studies are needed to shed light on this im-
portant issue.
Ethics of DBS in childhood
Several ethical issues need to be considered in DBS
treatment of pediatric patients with TS. As indicated in
the prior section, one important ethical question is
whether or not DBS should be considered in a teenager
with TS, given that tics decrease in 40% of TS patients
and disappear completely in another 40% of patients
during adolescence and young adulthood [2]. Based on
new insights and revised guidelines [17], patient’s age is
no longer a strict eligibility criterium for DBS treatment.
Instead, the eligibility for DBS treatment should be
based on a careful assessment of the benefits and risks
of the neurosurgical intervention for a given patient.
For some pediatric patients, the benefits of DBS can out-
weigh the risks associated with the intervention. As dis-
cussed in the prior section, DBS can offer substantial
clinical benefits to patients who suffer from otherwise in-
tractable TS with severe psychiatric comorbidities, self-
injurious behavior or even life-threatening symptoms [13,
44, 67, 68]. Another argument in favor of early DBS inter-
vention is that severe TS in adolescence is associated with
a high risk of bodily harm, disrupted cognitive and emo-
tional development, low self-esteem, and poor quality of
life [69]. This situation can jeopardize educational and job
opportunities, social interactions, and relationships with
peers. Thus delaying surgery in these young patients could
result in permanent harm to their cognitive, emotional,
and social development, even if the TS symptoms eventu-
ally subside with age. On the other hand, DBS is an inva-
sive treatment with potential surgical complications and
many adverse side effects.
Other factors are also relevant for determining
whether an adolescent patient may be a reasonable can-
didate for DBS. These include psychosocial factors, such
as the presence or absence of a stable and supportive so-
cial environment, as well as psychological factors, such
as the patient’s individual resilience and coping strat-
egies. Voluntary written informed consent must be
obtained from the pediatric patient and/or the legal
guardian before DBS treatment [69]. DBS is a potentially
powerful treatment for managing the clinical symptoms
of TS and its psychiatric comorbidities in select patients
who do not clinically respond to conventional treat-
ments. Finally, studies have provided evidence that DBS
can improve the motor and vocal tics in TS. An import-
ant goal of future DBS treatment studies is to improve
the patient’s clinical symptoms along with improving his
or her functional impairments and quality of life.
There is substantial inter-individual variability in the
clinical response to DBSA current clinical challenge lies
in finding a marker to predict the patient’s clinical re-
sponse to DBS. To date no genetic, biological, behavioral
or other type of marker has been identified that can ac-
curately predict the clinical response to DBS for individ-
ual patients. Longitudinal prospective studies, involving
large cohorts, standardized surgical procedures, and
multidimensional assessment protocols will be needed to
identify potential prognostic markers [44].. Finally, DBS
treatment for TS seems to be associated with a higher
infection risk [72]. Additional research is also needed to
determine whether the risk of infection or its complica-
tions differ between younger and older patients.
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Optimization of DBS treatment
Chronic high-frequency stimulation has been associated
with long-term improvement in motor and vocal tics
across multiple targets. It is unknown whether some pa-
tients with TS develop tolerance to continuous stimula-
tion or experience disease progression over the course of
the long-term treatment. The TAA Registry and other
studies have documented the adjustments made to the
stimulation parameters (e.g., increasing pulse voltage) to
maintain control of tics following DBS surgery [4, 32].
Such adjustments are made in an effort to maintain symp-
tomatic control but they could increase the total energy
delivered to the patient, thereby draining the battery more
quickly, leading to more frequent battery replacements
and increasing the burden on the patient involved. In the
near future, this problem may be resolved by rechargeable
technologies. The development and use of rechargeable
technologies could also resolve the increasing difficulties
in obtaining insurance and healthcare authorizations to
pay for battery replacements [73].
Adaptive deep brain stimulation
At present, most DBS systems function in an ‘open-loop’
mode, that is, the stimulation parameters are preset in
advance and cannot be changed or updated according to
the clinical symptoms of the patient or to underlying
pathophysiological changes in the brain. The classical
open-loop system, however, represents a static approach
to therapy within an inherently dynamic system [74]. In
contrast, responsive or adaptive DBS (aDBS) is designed
to function as a ‘closed-loop’ stimulation device, which
can be personalized according to the frequency and dur-
ation of a physiologic event or behavioral manifestation
[59, 75–78]. The closed-loop system in which stimula-
tion is dependent on functional neural feedback were
initially designed to improve the treatment of epilepsy
[79, 80]. Recent studies suggest that aDBS is a more ef-
fective approach than conventional DBS to treat epilepsy
and other neurological disorders, including PD [81, 82]
and essential tremor [83, 84].
The primary goal of aDBS is to widen the therapeutic
window. As opposed to closed-loop systems, aDBS can
be used to deliver stimulation according to the current
state of pathological activity, as indexed by real-time
changes in the patient’s brain electric signals. This
method may avoid the unwanted situation that stimula-
tion is given to patients when they are in a healthy, tic-
free state [78]. For DBS, the measurement of local field
potential (LFP) activity has been favored over microelec-
trode recordings of single neurons given that LFPs can
be readily measured from the implanted DBS leads [85,
86]. In one study, certain LFPs in the thalamus closely
linked to the generation of tics were identified in 3 pa-
tients with severe and intractable TS while undergoing
thalamic DBS [87]. Correspondingly, in line with the pu-
tative role of the thalamus in TS pathophysiology, it may
be hypothesized that the monitoring of thalamocortical
network activity could be useful in aDBS to detect the
presence of tics and associated pathological activity in
patients with TS [88].
Indeed, a case report has recently provided the first
evidence for the utility and feasibility of aDBS in TS
treatment [75]. In this study, a 27-year-old patient with
intractable TS was treated first with conventional, con-
tinuous DBS of the CM-Pf. After four years of stimula-
tion, the battery was depleted and surgically replaced.
On this occasion, the patient’s implant involved aDBS so
that stimulation was given only when tic-related, patho-
logical activity occurred in the CM-Pf. One year later,
the patient’s scores on the YGTSS and Modified Rush
Tic Rating Scale (MRTRS) were improved by 48 and
64%, respectively, when compared to the scores observed
before aDBS implantation surgery. These data not only
support the clinical utility of aDBS but also indicate that
this type of stimulation could be more effective than
conventional DBS for refractory TS.
A secondary goal of aDBS has been to reduce power
drain on the battery/neurostimulator (IPG). Recharge-
able IPG systems are unsuitable for a significant propor-
tion of patients [89]. Moreover, those patients who use
them would benefit if recharging occurred less fre-
quently. In this context, it is interesting to note that ef-
forts are being devoted to reducing rechargeable battery
size sufficiently to make skull-mounted IPGs possible
[90]. In the case study discussed earlier, it was observed
that the use of aDBS resulted in a 63% improvement in
the neurostimulator’s projected mean battery life when
compared with scheduled stimulation [75]. In addition,
there was a 145% improvement when compared with
duty-cycle-only therapy. The cumulative stimulation
dosage was also calculated. The calculated reductions in
the duty cycle and the scheduled duty cycle schemes
were 40 and 80%, respectively. The daily dosage, which
refers to the cumulative on time of the devices, for the
open-loop, duty-cycle, scheduled duty-cycle, and respon-
sive paradigms corresponded to 24, 2.82, 0.94, and 0.56
h, respectively, signifying that the estimated battery life
could be extended to 2.5 years for responsive stimulation
[75]. Thus, these data suggest that the use of aDBS treat-
ment for TS could also yield long-term economic and
practical benefits.
Functional connectivity profiles
No marker has so far been identified that accurately pre-
dicts the clinical response of patients with TS to DBS
treatment. Recently, resting-state fMRI studies have re-
ported some intriguing findings that could lead to the
development of a prognostic marker. These studies have
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focused on the structure and function of the so-called
‘default mode network’ (DMN), which refers to a widely
distributed brain network that is preferentially active
during rest and deactivated during task engagement
[91]. Altered functional integrity of the DMN has been
demonstrated in several neuropsychiatric disorders, in-
cluding TS. A study reported that functional connectiv-
ity in the DMN correlated negatively with tic severity in
a subgroup of TS-pure tic patients [92]. It has also been
reported that tic severity correlated negatively with ab-
normal intrinsic functional connectivity (iFC) between
the bilateral anterior cingulate cortices [93]. The latter
finding is in line with the hypothesis that impaired inter-
hemispheric functional connectivity contributes to the
pathophysiology of TS. This finding also suggests that
the iFC could serve as a quantitative biomarker for clin-
ical diagnosis. However, independent replication is re-
quired before this result can be well accepted.
In another study, the functional connectivity profile of
TS patients who showed a good clinical response to
CM-Pf DBS were compared with that of patients who
displayed a poor clinical response [94]. The functional
profile was defined in terms of connection between the
volumes of tissue activated (VTAs) of the active DBS
contact and the cortical areas. The results showed that
responders had VTAs that were closely linked to the
right frontal middle gyrus, the left frontal superior sulci
region, and the left cingulate sulci region, whereas poor
responders had VTAs that were only loosely related to
these regions [94]. Although this study was limited by
small sample size (n = 5 patients), the results indicate
that the assessment of VTA-based functional connectiv-
ity profiles could help in predicting the patient’s clinical
response to CM-Pf DBS.
In conclusion, the assessment of functional connectiv-
ity profiles seems to be a promising approach to identi-
fying diagnostic or prognostic markers in TS. Functional
effectivity profile assessment may similarly be useful in
improving clinical outcome following STN–DBS in
Parkinson’s disease [95]. It has also been postulated that
long-term DBS can restore brain functional connectivity
at a global level [96]. Accordingly, an important topic
that warrants further research is the relationship be-
tween preoperative functional connectivity profiles and
clinical outcomes in TS.
Structural connectivity profiles
Neuroimaging studies have also assessed the structural
connections in the human brain, usually employing re-
gional measures. In a study, probabilistic stimulation at-
lases were used to identify anatomical regions that may
predict the therapeutic response to DBS for TS [42].
However, the stimulation location relative to structural
anatomy alone did not sufficiently predict the efficacy of
DBS on tic severity. This study, however, focused on a
single focal brain site. As brain regions are not isolated
structures and the connectivity between regions is cru-
cial for normal brain function, there has been a recent
shift to methods that study the connectivity between
regions. For example, tractography based on diffusion
tensor imaging (DTI) can be used to identify the prob-
abilistic structural connectivity of the site of stimulation
and to detect the brain networks that contribute to
symptom improvement across multiple surgical targets
[97]. Also, DTI studies have shown altered properties of
white matter microstructure in cortico-striato-thalamo-
cortical circuitry in patients with TS [98, 99]. In another
study, a large sample of young patients (age range, 8–21)
were measured using tract-based spatial statistics and
probabilistic tractography [100]. The results demon-
strated both marked and wide spread decreases in axial
diffusivity together with altered white matter connectiv-
ity. The tic severity was associated with increased con-
nectivity between primary motor cortex and the caudate
nuclei [100]. These results provide putative evidence that
altered connectivity of the insula might play a pivotal
role in the pathogenesis of TS.
Tractography has been used to analyze the network ef-
fects of DBS for treatment-refractory OCD patients [101,
102], demonstrating that optimal therapeutic results are
associated with the activation of specific fiber pathways.
In OCD DBS targeting NAc/ALIC, the degree of con-
nectivity between stimulation sites and medial and lat-
eral prefrontal cortices significantly predicted clinical
improvement [102]. These results also indicate that con-
nectivity of the site stimulation plays a role in mediating
the clinical response to DBS. Selection and refinement
of DBS targets based on structural connectivity by trac-
tography could help in improving clinical outcomes and
avoiding stimulation related adverse events of DBS ther-
apy for TS.
As discussed before, DBS of the Forel’s field seems to
be effective for tics and comorbid symptoms in TS, but
the exact location of this target cannot be easily be esti-
mated from the anatomical information provided by
standard MRI and CT scans. Its reference coordinates
obtained from stereotactic brain atlases or target using
the surrounding structures as landmarks [51]. Direct tar-
geting of the Forel’s field and their connective fiber
tracts might be achieved using tractography guided ap-
proaches. Likewise, the superolateral branch of the med-
ial forebrain bundle (slMFB) seems to be anatomically
and functionally connected with DBS targets used to
treat major depressive disorder (MDD), such as the
NAc/ALIC [103]. In another study, tractography was
useful for localizing and implanting DBS targeting the
slMFB, serving to modulate subcortical and cortical
reward-related pathways assumed to be dysfunctional in
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MDD [104]. The results showed, indeed, that direct
white-matter modulation of slMFB fibers achieved desir-
able anti-depressive effects. Moreover, a double-blinded,
randomized study involving 34 patients with either
tremor-dominant Parkinson’s disease or essential tremor
demonstrated the clinical utility of tractography. The re-
sults demonstrated that the tractography-guided lead
placement produced a more enduring tremor control
and fewer adverse effects compared with lead placement
using conventional landmarks [105]. It also seems that
tractography is feasible and effective in identifying the
optimal DBS trajectory [106]. Surgeons can perform
DBS procedures using the anatomical information from
preoperative DTI studies for accurate DBS implantation.
Conclusions
Tourette syndrome (TS) is a childhood-onset neuro-
psychiatric disorder characterized by the presence of
multiple motor and vocal tics. TS usually co-occurs with
one or more psychiatric disorders. Although behavioral
and pharmacological treatments for TS are available,
some patients do not profit from these treatments and
continue to display significant and disabling symptoms.
For severe and refractory cases of TS, DBS could provide
an alternative treatment option. Important issues
involved in DBS treatment include patient selection,
clinical assessment including psychiatric comorbidities,
selection of clinical outcomes, assessment of patient
risks and benefits, DBS target selection, and treatment
optimization. Recent recommendations for TS DBS have
been published by the TAA and the AAN.
DBS seems to offer a valuable treatment option for se-
vere and refractory cases of TS. Although several effect-
ive targets have been identified, different targets are
associated with different therapeutic effects and different
adverse-event profiles. However, the clinically best target
or combination of targets remains to be determined.
Multiple targets and/or DBS combined with radiosurgery
are both promising approaches to improve clinical out-
comes in carefully selected patients with severe psychi-
atric comorbidities. Individual patient differences in
clinical response to TS DBS have been substantial, and a
marker that can predict individual response has not yet
been identified. In DBS of pediatric patients, clinicians
are faced with various ethical issues, which need to be
carefully considered on a case by case basis. The effect
of conventional open-loop DBS on TS symptoms ap-
pears clinically significant, but newly developed, closed-
loop DBS (aDBS) could greatly advance treatment for
TS by adjusting in real-time the stimulation according to
the clinical state of the patient and the underlying patho-
logical network activity.
Finally, TS DBS should not be performed without an
experienced multidisciplinary team, including a
psychiatrist for pre- and post-operative clinical assess-
ments. It is necessary to confirm the DSM-V diagnosis,
to rule out psychogenic tics, and to assess psychiatric co-
morbidities. Age is not an eligibility criterion for DBS,
but a multidisciplinary board should evaluate risks and
benefits for each patient while taking into consideration
the ethical issues relevant to pediatric populations.
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